Rates of allergic reactions were very low in an Australian school population that had received 380,000 doses of HPV vaccine.
The quadrivalent human papillomavirus (HPV) vaccine (Gardisil), which targets the viral types that cause cervical cancer and genital warts, is the most recent addition to the list of routinely recommended vaccines for adolescent girls. Because licensure is recent, safety data are relatively limited. Investigators in Australia (where the vaccine has been included in the national immunization program since April 2007) conducted a retrospective cohort study to evaluate vaccine hypersensitivity reactions.
Thirty-five girls (age range, 12–19) in two states were suspected to be hypersensitive to the vaccine. Of these, 25 agreed to follow-up evaluations. After receiving the first dose, 23 of the 25 girls had experienced reactions, 13 of which were …
Reviewing Author
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)